"CA-19-9 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.
| Descriptor ID |
D018395
|
| MeSH Number(s) |
D23.050.285.050.119 D23.050.301.290.544.119 D23.050.550.325.119 D23.050.705.230.544.119 D23.101.140.075.119
|
| Concept/Terms |
CA-19-9 Antigen- CA-19-9 Antigen
- Antigen, CA-19-9
- CA 19 9 Antigen
- CA 19.9 Antigen
- Antigen, CA 19.9
- Gastrointestinal Cancer Antigen
- Cancer Antigen, Gastrointestinal
- CA 19-9 Antigen
- Antigen, CA 19-9
- Antigen CA-19-9
- Antigen CA 19 9
- CA-19-9, Antigen
|
Below are MeSH descriptors whose meaning is more general than "CA-19-9 Antigen".
Below are MeSH descriptors whose meaning is more specific than "CA-19-9 Antigen".
This graph shows the total number of publications written about "CA-19-9 Antigen" by people in this website by year, and whether "CA-19-9 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CA-19-9 Antigen" by people in Profiles.
-
Appendiceal Adenocarcinoma Cytoreduction Outcomes and Perioperative Serum Tumor Marker Levels. JAMA Netw Open. 2026 May 01; 9(5):e2610569.
-
Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Netw Open. 2024 02 05; 7(2):e240260.
-
Stereoselective Synthesis of Sialyl Lewisa Antigen and the Effective Anticancer Activity of Its Bacteriophage Q? Conjugate as an Anticancer Vaccine. Angew Chem Int Ed Engl. 2023 11 20; 62(47):e202309744.
-
Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer. Cancer Prev Res (Phila). 2021 07; 14(7):729-740.
-
Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol. 2015 Aug; 22(8):2578-84.
-
Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. BMC Cancer. 2013 Sep 03; 13:404.
-
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014 May; 16(5):430-8.
-
Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 2013 Jul; 20(7):2197-203.
-
Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9. Clin Chem. 2013 Jan; 59(1):22-31.
-
Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One. 2011; 6(12):e29180.